(“Omega” or the “Company” or the “Group”)

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the appointment of Jeremy Millard as Non-Executive Director to the Board with immediate effect, after a thorough search process.

The Board consider Jeremy to be independent and it is anticipated that he will, in due course, be appointed to the Audit and Remuneration Committees of the Company.

Jeremy has 20 years investment banking experience and was previously a partner at Smith Square Partners LLP where he provided strategic and corporate advice to clients in the science, technology and telecommunications sectors, prior to which he headed up the technology practice at Rothschild in London. Jeremy is currently a Non-Executive Director and chairman of the audit committee of AIM-listed Idox plc and a Non-Executive Director of AIM-listed Ilika Plc.

Bill Rhodes, Interim Non-Executive Chairman of the Company said: “We are delighted to have Jeremy join the Omega Board. With his relevant financial experience, familiarity with AIM-listed companies and his energy and enthusiasm for Omega, we feel confident that his appointment will bring immediate value to our Board and the Company in general.”

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Mr Jeremy Howard Millard, age 47, is the brother-in-law of Richard Sneller, who has a substantial shareholding in the Company.

Current Directorships / Partnerships:

Idox plc
Ilika Plc
Blackbullion Limited
Iridium Corporate Finance Limited
Previous Directorships / Partnerships (held in the past five years)
Solar Communications Group Limited
Smith Square Partners LLP
Mr Millard does not currently hold any ordinary shares in the Company. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.